



GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD; Relovair(TM) programme expanded by start of large Phase IIIb COPD outcomes study

February 3, 2011

GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD; Relovair programme expanded by start of large Phase IIIb COPD outcomes study